title: Raloxifene has favourable effects on metabolic parameters but has no effect on left ventricular function in postmenopausal women.
abstract: In this prospective randomized study, we investigated the effect of raloxifene on the echocardiographic parameters of left ventricular diastolic and systolic function and on blood levels of lipids, homocysteine, and lipoprotein (a) in postmenopausal osteoporotic patients and compared the results with those treated with risedronate. A total of 44 women were included in the study. Patients were randomized into two groups. Twenty-two patients received raloxifene 60 mg/day (group 1), and 22 patients received risedronate 5mg/day (group 2; the control group). All patients underwent quantitative two-dimensional pulsed wave Doppler and tissue Doppler echocardiography. Levels of fasting total-C, HDL-C, LDL-C, triglycerides, homocysteine, and lipoprotein (a) were measured. All echocardiographic and biochemical parameters were assessed at the beginning of the study and after the 6-month follow-up. Demographic characteristics and baseline metabolic and echocardiographic parameters were similar in the two groups. After 6 months of the therapy, serum levels of total-C, LDL-C, and homocysteine decreased significantly (P=.04, P=.02, P=.008, respectively) in the treated group when compared with the control group. All echocardiographic measurements except a wave from level of basal interventricular septum were similar in the two groups both before and after 6 month of therapy. In the control group, a wave from level of basal interventricular septum increased significantly (P=.019). In conclusions raloxifene may decrease serum levels of total-C, LDL-C, and homocysteine in postmenopausal osteoporotic patients and raloxifene therapy seems to have no significant effect on left ventricular systolic and diastolic function.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.
authors.forename: Mesut
authors.initials: M
authors.lastname: Oktem
authors.forename: Ilyas
authors.initials: I
authors.lastname: Atar
authors.forename: Hulusi B
authors.initials: HB
authors.lastname: Zeyneloglu
authors.forename: Aylin
authors.initials: A
authors.lastname: Yildirir
authors.forename: Esra
authors.initials: E
authors.lastname: Kuscu
authors.forename: Haldun
authors.initials: H
authors.lastname: Muderrisoglu
mesh_terms: D000368:Aged; D003971:Diastole / Q000187:drug effects; D018619:Echocardiography, Doppler, Pulsed; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*; D013599:Systole / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D008055:Lipids; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride